DOCSLIB.ORG

Contents MEDLINE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Risks Antenatal depression - Search Strategy Page 1 of 71 Contents MEDLINE ................................................................................................................................... 1 EMBASE ...................................................................................................................................16 PsycINFO .................................................................................................................................34 CINAHL.....................................................................................................................................48 Cochrane CENTRAL .................................................................................................................59 Web of Science .........................................................................................................................69 MEDLINE # ▲ Searches 1 exp Psychotherapy/ 2 psychotherap*.mp. 3 (psychoeducational adj4 therap*).mp. 4 exp Cognitive Therapy/ 5 (cognitive adj4 therap*).mp. 6 (interpersonal adj4 therap*).mp. 7 counsel*.mp. 8 (Supportive adj4 interaction).mp. 9 (psychologic* adj4 therap*).mp. 10 (no* adj4 pharmac* adj4 therap*).mp. 11 (no* adj4 medic* adj4 therap*).mp. 12 exp Phototherapy/ 13 Phototherap*.mp. 14 "Photo therapy".mp. Risks Antenatal depression - Search Strategy Page 2 of 71 15 exp Exercise/ 16 exp Exercise Therapy/ 17 kinesiotherap*.mp. 18 exercise*.mp. 19 exp Yoga/ 20 yoga.mp. 21 exp Acupuncture Therapy/ 22 Acupuncture.mp. 23 exp Sleep Deprivation/ 24 (sleep* adj4 depriv*).mp. 25 exp Herbal Medicine/ 26 (herbal* adj4 medic*).mp. 27 (herbal* adj4 therap*).mp. 28 exp Complementary Therapies/ 29 (complement* adj4 medic*).mp. 30 (complement* adj4 therap*).mp. 31 (alternat* adj4 medic*).mp. 32 (alternat* adj4 therap*).mp. 33 (psychosocial* adj4 therap*).mp. 34 exp Mindfulness/ 35 mindful*.mp. 36 (accept* adj4 therap*).mp. 37 (commit* adj4 therap*).mp. 38 exp Behavior Therapy/ 39 (behavio* adj4 therap*).mp. 40 (problem adj4 solv* adj4 therap*).mp. 41 exp Psychoanalytic Therapy/ Risks Antenatal depression - Search Strategy Page 3 of 71 42 (psychoanal* adj4 therap*).mp. 43 (psychodynamic adj4 therap*).mp. 44 (dynamic adj4 therap*).mp. 45 bibliotherap*.mp. 46 (guided adj4 self adj4 help).mp. 47 (distract* adj4 therap*).mp. 48 (light adj4 therap*).mp. 49 exp Hydrotherapy/ 50 hydrotherap*.mp. 51 exp Meditation/ 52 meditat*.mp. 53 exp Music Therapy/ 54 music* therap*.mp. 55 exp Animal Assisted Therapy/ 56 ((animal or pet* or dog* or cat* or canine or equine or horse* or dolphin*) adj4 therap*).mp. 57 exp Equine-Assisted Therapy/ 58 hippotherap*.mp. 59 exp Massage/ 60 massag*.mp. 61 exp Therapeutic Touch/ 62 (therap* adj4 touch*).mp. 63 reiki.mp. 64 exp Amino Acids/ 65 amino acid*.mp. 66 exp Vitamins/ 67 vitamin*.mp. 68 exp Minerals/ Risks Antenatal depression - Search Strategy Page 4 of 71 69 mineral*.mp. 70 exp Inositol/ 71 Inositol.mp. 72 methyl-folate*.mp. 73 (omega-3 adj4 fatty adj4 acids).mp. 74 exp S-Adenosylmethionine/ 75 adenosylmethionine.mp. 76 "S-adenosyl-L-methionine".mp. 77 exp Hypericum/ 78 Hypericum.mp. 79 (John* adj4 wort).mp. 80 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 81 exp pregnancy/ 82 exp pregnant woman/ 83 pregnan*.mp. 84 gestation*.mp. 85 exp Gravidity/ 86 gravid*.mp. 87 (expectant adj4 mother*).mp. 88 exp Pregnancy Complications/ 89 (pregnan* adj4 complication*).mp. 90 exp Pregnancy Outcome/ 91 (pregnan* adj4 outcome*).mp. Risks Antenatal depression - Search Strategy Page 5 of 71 92 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 93 exp Depression/ 94 exp Depressive Disorder/ 95 depres*.mp. 96 exp Mood Disorders/ 97 (mood adj4 disorder*).mp. 98 exp Dysthymic Disorder/ 99 dysthymi*.mp. 100 exp Depressive Disorder, Major/ 101 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 102 92 and 101 103 untreat*.mp. 104 ("not" adj4 treat*).mp. 105 (no adj4 treat*).mp. 106 (no adj4 therap*).mp. 107 (usual adj4 treat*).mp. 108 placebo.mp. 109 nonmedic*.mp. 110 ((no or "not" or non) adj4 (medic* or antipedres* or SSRI*)).mp. 111 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 112 exp Premature Birth/ 113 prematurit*.mp. 114 ((premature or "pre mature" or "preterm" or "pre term") adj4 (birth* or deliver* or labo*)).mp. 115 (premature adj4 birth*).mp. 116 ("pre mature" adj4 birth*).mp. 117 (preterm adj4 birth*).mp. 118 ("pre term" adj4 birth*).mp. Risks Antenatal depression - Search Strategy Page 6 of 71 119 exp Gestational Age/ 120 (gestational adj4 age*).mp. 121 exp Small for Gestational Age/ 122 exp Fetal Growth Retardation/ 123 (fetal adj4 grow*).mp. 124 exp Fetal Macrosomia/ 125 macrosomia.mp. 126 exp Birth Weight/ 127 (birth adj4 weight*).mp. 128 "birthweight".mp. 129 exp Low Birth Weight/ 130 (weight* adj4 newborn*).mp. 131 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 132 exp Antidepressive Agents/ 133 antidepress*.mp. 134 anti-depress*.mp. 135 exp Antidepressive Agents, Second-Generation/ 136 (psych* adj4 medic*).mp. 137 exp Drug Therapy/ 138 (drug* adj4 therap*).mp. 139 pharmacotherap*.mp. 140 pharmaco* therap*.mp. 141 pharmaco* treat*.mp. 142 SSRI*.mp. 143 exp Serotonin Uptake Inhibitors/ 144 (Serotonin adj4 Uptake adj4 Inhibitor*).mp. 145 (Serotonin adj4 reuptake adj4 Inhibitor*).mp. Risks Antenatal depression - Search Strategy Page 7 of 71 146 exp Citalopram/ 147 Citalopram.mp. 148 Escitalopram.mp. 149 exp Fluoxetine/ 150 Fluoxetine.mp. 151 exp Fluvoxamine/ 152 Fluvoxamine.mp. 153 exp Paroxetine/ 154 Paroxetin*.mp. 155 exp Sertraline/ 156 Sertralin*.mp. 157 exp Serotonin Antagonists/ 158 (Serotonin adj4 Antagonist*).mp. 159 Etoperidone.mp. 160 Nefazodone.mp. 161 exp Trazodone/ 162 Trazodone.mp. 163 ((norepinephrine or noradrenaline or neurotransmitt* or dopamin*) and (uptake or reuptake or re-uptake or "re uptake")).mp. 164 SNRI*.mp. 165 Desvenlafaxine.mp. 166 Desvenlafaxin*.mp. 167 Duloxetin*.mp. 168 Levomilnacipran.mp. 169 Milnacipran.mp. 170 Venlafaxin*.mp. 171 exp Adrenergic Uptake Inhibitors/ 172 (Adrenergic adj4 Uptake adj4 Inhibitors).mp. Risks Antenatal depression - Search Strategy Page 8 of 71 173 (Adrenergic adj4 reuptake adj4 Inhibitors).mp. 174 exp Bupropion/ 175 amfebutamon*.mp. 176 Bupropion.mp. 177 Atomoxetin*.mp. 178 Reboxetin*.mp. 179 exp Viloxazine/ 180 Viloxazin*.mp. 181 NDRI*.mp. 182 Amineptin*.mp. 183 exp Nomifensine/ 184 Nomifensin*.mp. 185 exp Antidepressive Agents, Tricyclic/ 186 tryciclic*.mp. 187 exp Amitriptyline/ 188 Amitriptylin*.mp. 189 Amitriptylinoxide.mp. 190 exp Amoxapine/ 191 Amoxapin*.mp. 192 Butriptylin*.mp. 193 exp Clomipramine/ 194 Clomipramin*.mp. 195 Chlomipramin*.mp. 196 Chlorimipramin*.mp. 197 Demexiptilin*.mp. 198 Dimetacrin*.mp. 199 exp Dothiepin/ Risks Antenatal depression - Search Strategy Page 9 of 71 200 Dothiepin*.mp. 201 dosulepin*.mp. 202 exp Doxepin/ 203 Doxepin*.mp. 204 exp Imipramine/ 205 Imipramin*.mp. 206 exp Iprindole/ 207 Iprindol*.mp. 208 exp Lofepramine/ 209 Lofepramin*.mp. 210 Melitracen.mp. 211 Metapramin*.mp. 212 Nitroxazepin*.mp. 213 exp Nortriptyline/ 214 Nortriptylin*.mp. 215 Noxiptilin*.mp. 216 exp Opipramol/ 217 Opipramol.mp. 218 Pipofezin*.mp. 219 Propizepin*.mp. 220 exp Protriptyline/ 221 Protriptylin*.mp. 222 Quinupramin*.mp. 223 Tianeptin*.mp. 224 exp Trimipramine/ 225 Trimipramin*.mp. 226 Agomelatin*.mp. Risks Antenatal depression - Search Strategy Page 10 of 71 227 Alaproclate.mp. 228 exp Perphenazine/ 229 Perphenazin*.mp. 230 Befloxaton*.mp. 231 exp Benactyzine/ 232 Benactyzin*.mp. 233 Binospiron*.mp. 234 Brofaromin*.mp. 235 exp Bupropion/ 236 Bupropion.mp. 237 Caroxazon*.mp. 238 Cianopramin*.mp. 239 Cilobamin*.mp. 240 Cimoxaton*.mp. 241 exp Clorgyline/ 242 Clorgylin*.mp. 243 Clovoxamin*.mp. 244 exp Desipramine/ 245 Desipramin*.mp. 246 Dibenzepin*.mp. 247 Diclofensin*.mp. 248 Edivoxetin*.mp. 249 Femoxetin*.mp. 250 Fluotracen.mp. 251 exp Iproniazid/ 252 Iproniazid.mp. 253 Ipsapiron*.mp. Risks Antenatal depression - Search Strategy Page 11 of 71 254 exp Isocarboxazid/ 255 Isocarboxazid.mp. 256 exp Maprotiline/ 257 Maprotilin*.mp. 258 exp Mianserin/ 259 Mianserin*.mp. 260 Minaprin*.mp. 261 mirtazapin*.mp. 262 exp Moclobemide/ 263 Moclobemid*.mp. 264 exp Monoamine Oxidase/ 265 Monoamine Oxidase.mp. 266 MAO*.mp. 267 RIMA*.mp. 268 exp Nialamide/ 269 Nialamid*.mp. 270 exp Norfenfluramine/ 271 Norfenfluramin*.mp. 272 Oxaflozan*.mp. 273 exp Phenelzine/ 274 Phenelzin*.mp. 275 Pheniprazin*.mp. 276 exp Pirenzepine/ 277 Pirenzepin*.mp. 278 Pirlindol*.mp. 279 Pivagabin*.mp. 280 exp Pizotyline/ Risks Antenatal depression - Search Strategy Page 12 of 71 281 Pizotylin*.mp. 282 pizotifen.mp. 283 exp Rolipram/ 284 Rolipram.mp. 285 exp Scopolamine Hydrobromide/ 286 Scopolamin*.mp. 287 exp Selegiline/ 288 Selegilin*.mp. 289 Setiptilin*.mp. 290 teciptilin*.mp. 291 Thozalinon*.mp. 292 Toloxaton*.mp. 293 exp Tranylcypromine/ 294 Tranylcypromin*.mp. 295 Vilazodon*.mp. 296 Viqualin*.mp. 297 Vortioxetin*.mp. 298 Zalospiron*.mp. 299 Amfebutamon*.mp. 300 Tyrima.mp. 301 Deprenyl.mp. 302 Pertrofan*.mp. 303 Dosulepin*.mp. 304 Teciptilin*.mp. 305 exp Anticonvulsants/ 306 Anticonvuls*.mp. 307 neurolep*.mp. Risks Antenatal depression - Search Strategy Page 13 of 71 308 exp Antipsychotic Agents/ 309 antipsychotic*.mp. 310 exp Benzodiazepines/ 311 Benzodiazepin*.mp. 312 exp Carbamazepine/ 313 Carbamazepin*.mp. 314 exp Clozapine/ 315 Clozapin*.mp. 316 exp Selegiline/ 317 Selegilin*.mp. 318 exp Haloperidol/ 319 Haloperidol*.mp. 320 lamotrigin*.mp. 321 exp Lithium/ 322 Lithium.mp. 323 olanzapin*.mp. 324 quetiapin*.mp. 325 exp Risperidone/ 326 Risperidon*.mp. 327 (tetracyclic adj4 therap*).mp. 328 exp Valproic Acid/ 329 Valproic Acid.mp.
Recommended publications
  • Methylphenidate Hydrochloride

    Methylphenidate Hydrochloride

    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
  • Implications in the Management of Depression and Anxiety

    Implications in the Management of Depression and Anxiety

    Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Year: 2016 Volume: 12 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Montoya et al Running head recto: Noradrenergic paradox in depression and anxiety open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S91311 Open Access Full Text Article REVIEW The noradrenergic paradox: implications in the management of depression and anxiety Alonso Montoya1 Abstract: Both major depressive disorder and the anxiety disorders are major causes of disability Robert Bruins1 and markedly contribute to a significant global burden of the disease worldwide. In part because Martin A Katzman2 of the significant socioeconomic burden associated with these disorders, theories have been devel- Pierre Blier3 oped to specifically build clinical treatment approaches. One such theory, the monoaminergic hypothesis, has led to the development of several generations of selective and nonselective inhibi- 1Eli Lilly Canada Inc, 2START Clinic for the Mood and Anxiety Disorders, tors of transporters of serotonin and norepinephrine, with the goal of augmenting monoaminergic Toronto, 3Mood Disorders Research transmission. These efforts have led to considerable success in the development of antidepressant Unit, Institute of Mental Health therapeutics. However, there is a strong correlation between enhanced noradrenergic activity Research, University of Ottawa, Ottawa, ON, Canada and fear and anxiety. Consequently, some physicians have expressed concerns that the same enhanced noradrenergic activity that alleviates depression could also promote anxiety. The fact that the serotonergic and noradrenergic reuptake inhibitors are successfully used in the treatment For personal use only. of anxiety and panic disorders seems paradoxical. This review was undertaken to determine if any clinical evidence exists to show that serotonergic and noradrenergic reuptake inhibitors can cause anxiety.
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
  • Product List March 2019 - Page 1 of 53

    Product List March 2019 - Page 1 of 53

    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA

    Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Potentiation of the Mydriatic Effect of Norepinephrine in the Rabbit After

    Potentiation of the Mydriatic Effect of Norepinephrine in the Rabbit After

    Reports Potentiation of the mydriatic effect of change.7 After topical application of the mono- norepinephrine in the rabbit after amine releaser Ro 4-1284 to the eyes of rabbits monoamine oxidase inhibition. BRENDA K. pretreated with these MAO inhibitors, however, COLASANTI AND ERNST H. BARANY. pupillary dilation ensued. As in the case of re- sponses of other peripheral tissues, the response Dose-response curves of pupillary dilation after topical of the iris to indirectly acting sympathomimetic administration of norepinephrine or methoxamine have agents has been shown to be potentiated in hu- been determined in rabbits after chronic inhibition of man subjects undergoing treatment with MAO in- ocular monoamine oxidase by treatment with pargyline hibitors.8 or pheniprazine. Eyes treated with either monoamine ox- In the present communication, we report a idase inhibitor showed an enhanced responsiveness to potentiation of the mydriatic response of the rab- the mydriatic effect of norepinephrine given either topi- bit eye to norepinephrine after prior treatment cally or intravenously. Increments in pupil size of the with MAO inhibitors. This increase in sensitivity treated and control eyes in response to methoxamine applied topically, on the other hand, were the same. of the iris contrasts with the unaltered responses of These results suggest that monoamine oxidase may play a other peripheral organs and tissues to directly act- 2 role in the iris as one factor influencing the concentration ing catecholamines after MAO inhibition. of norepinephrine at the receptors. Methods. Adult male albino rabbits weighing 2 to 3 kg were used in these experiments. Pheni- The principal mechanism for physiological inac- prazine (Draco, Lund and Merrell—National tivation of norepinephrine released from adren- Laboratories, Ohio) was applied topically by mi- ergic nerve endings for action on autonomic effec- crodrop to the right eyes of three groups of six tor organs involves reuptake into the prejunctional rabbits once daily for 7 days.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit

    Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit

    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).